{"id":531541,"date":"2021-02-24T07:38:01","date_gmt":"2021-02-24T07:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531541"},"modified":"2021-02-24T07:38:01","modified_gmt":"2021-02-24T07:38:01","slug":"secondary-hyperparathyroidism-market-size-share-2030-secondary-hyperparathyroidism-market-research-report-market-analysis-market-growth-trends-and-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/secondary-hyperparathyroidism-market-size-share-2030-secondary-hyperparathyroidism-market-research-report-market-analysis-market-growth-trends-and-forecast_531541.html","title":{"rendered":"Secondary Hyperparathyroidism Market Size & Share 2030 | Secondary Hyperparathyroidism Market Research Report, Market Analysis, Market Growth, trends and Forecast"},"content":{"rendered":"
\"Secondary<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Secondary Hyperparathyroidism – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Secondary Hyperparathyroidism – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>.<\/p>\n

DelveInsight’s “Secondary Hyperparathyroidism Market Report 2030<\/strong><\/a>” delivers an in-depth understanding of the Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

Secondary hyperparathyroidism (SHPT) occurs when the parathyroid glands become enlarged and release too much PTH, causing a high blood level of PTH. Parathyroid hormone controls the level of calcium is in blood and within bones. There are several reasons why this happens in patients with kidney disease:<\/div>\n
\n
Higher blood phosphorus levels<\/div>\n
The kidneys cannot make active vitamin D (needed to absorb calcium)<\/div>\n
Lower blood calcium levels<\/div>\n
 <\/div>\n
\n
Secondary Hyperparathyroidism Treatment Options:<\/strong><\/a><\/div>\n
 <\/div>\n
1. Drugs:  There are three types of drugs for secondary hyperparathyroidism—vitamin D supplements, active vitamin D (or vitamin D analogs) and cinacalcet.<\/div>\n
 <\/div>\n
2. Surgery: Parathyroidectomy is an operation that removes the parathyroid glands. This operation is only for very severe cases of hyperparathyroidism that cannot be managed with medicine.<\/div>\n
 <\/div>\n
3. Controlling Your Blood Phosphorus Levels: Since high blood phosphorus levels increase the release of PTH, it is important to keep your blood phosphorus in normal range using diet and phosphate binders. <\/div>\n
\n

Click here and get a detailed report.<\/strong><\/a><\/p>\n

Secondary Hyperparathyroidism Epidemiology Analysis:<\/strong><\/p>\n

Secondary hyperparathyroidism is common among patients with vitamin D deficiency and chronic kidney disease. It has been observed that medical therapy does not work in up to 25% of patients and surgery is sometimes necessary. Since about half, the world population is vitamin D deficient, and about 1\/7 have CKD, it is important to understand the condition in depth.<\/p>\n

As per the study conducted by Laura Cotoi et al. (2019), The prevalence in Europe of Secondary hyperparathyroidism among patients with requiring renal replacement therapies is estimated at 43.8% in France, 46.8% in Russia, and 42.9% in the United Kingdom. United States has a prevalence of 54%.<\/p>\n

Secondary Hyperparathyroidism Key pharma player involved:<\/strong><\/p>\n

1. Sanwa Kagaku Kenkyusho<\/p>\n

2. TaiRx<\/p>\n

Secondary Hyperparathyroidism Emerging Therapies:<\/strong><\/p>\n

1. SK-1403<\/p>\n

2. TRX 711<\/p>\n

Request for a free sample report.<\/strong><\/a><\/p>\n

Table of contents<\/strong><\/p>\n

1 Key Insight
2 Executive Summary of Secondary Hyperparathyroidism
3 Secondary Hyperparathyroidism Market Overview at a Glance
4 Disease Background and Overview: Secondary Hyperparathyroidism
5 Case Reports
6 Secondary Hyperparathyroidism Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Secondary Hyperparathyroidism Treatment and Medical Practices
11 Unmet needs
12 Secondary Hyperparathyroidism Marketed Drugs
13 Secondary Hyperparathyroidism Emerging Drugs
14 Secondary Hyperparathyroidism 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Secondary Hyperparathyroidism Market Drivers
19 Secondary Hyperparathyroidism Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong> <\/p>\n<\/div>\n<\/div>\n<\/div>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Secondary Hyperparathyroidism – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531541","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531541"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531541\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}